home / stock / gcan / gcan news

GCAN News and Press, GammaCan International Inc.

Stock Information
Company Name: GammaCan International Inc.
Stock Symbol: GCAN
Market: OTC
Website: gcanrx.com
Menu
GCAN GCAN Quote GCAN Short GCAN News GCAN Articles GCAN Message Board
Get GCAN Alerts

News, Short Squeeze, Breakout and More Instantly...
GCAN - GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

BALTIMORE, MD, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has comp...
GCAN - GCANRx Featured in American Journal of Endocannabinoid Medicine

BALTIMORE, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that the Company and its scien...

GCAN - GCANRx Announces Approval of Phase II Clinical Trial to Treat Autism Related Spectrum Disorders

BALTIMORE, July 05, 2023 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a publicly traded biopharmaceutical company pioneering development of next generation therapeutics is pleased to announce that it has been granted fina...

GCAN - Greater Cannabis rises 25% on submitting phase 2 trial application to treat autism in Israel

Greater Cannabis ( OTCQB:GCAN ) said on Friday it had submitted a clinical trial application to the Israel Ministry of Health for approval of a Phase 2 clinical trial for its neuropsychiatric cannabinoid therapy. ( OTCQB:GCAN ) has risen 25% . The Company intends t...
GCAN - GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders

BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics today announced that it has submitted a clinical tri...

GCAN - GCANRx Strategic Advisor Dr. Adi Aran to be Interviewed by Dr. Sanjay Gupta on CNN Cannabis Special

The 6 th Installment in the Award-winning Series by Dr. Sanjay Gupta will Air on Sunday, December 19 th at 9pm ET BALTIMORE, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCA...

GCAN - GCANRx Appoints Renowned Cannabinoid Researcher Dr. Adi Aran as Strategic Advisor

Dr. Aran will be focused on furthering development of the therapeutic pipeline, advancing the clinical study program and supporting IP and regulatory strategies. BALTIMORE, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or ...
GCAN - Greater Cannabis initiates neuropsychiatric cannabinoid therapy preclinical study

Greater Cannabis Company (OTCQB:GCAN) has begun the preclinical phase of assessing its novel neuropsychiatric cannabinoid therapy. The company’s announcement of the preclinical study follows the signing of a license and research agreement with Shaare Zedek Scientific. Greater Cannabis&...

GCAN - GCANRx Announces Initiation of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

BALTIMORE, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid therapeutics and consumer products today announced that it has be...

GCAN - GCANRx Signs Licensing Agreement with Shaare Zedek Scientific for Innovative Neuropsychiatric Cannabinoid Therapy

BALTIMORE, Aug. 19, 2021 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTCQB: GCAN) a cannabis innovator specializing in the development of pharmaceutical and consumer products is pleased to announce it has entered into a licensi...
Next 10